Celgene works to calm down anxious investors, promising to re-file ozanimod at the FDA in early 2019
For weeks now, analysts have been fretting over the future of Celgene’s $CELG multiple sclerosis drug ozanimod. Turned away at the FDA’s front door with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
